Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes

Kidney International

Volumn 64, Issue 2, 2003, Pages 565-571

  Qin, Jie ^b   Zhang, Zhili ^b   Liu, Jie ^b   Sun, Liao ^b   Hu, Ling ^b   Cooper, Mark E ^b   Cao, Zemin ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b NONE

Author keywords

Albuminuria; Angiotensin II antagonist; Diabetes; Statins; TGF 1; VEGF

Indexed keywords

ALBUMIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CHOLESTEROL; CREATININE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; SIMVASTATIN; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG POTENTIATION; EXPERIMENTAL DIABETES MELLITUS; FEMALE; GENE EXPRESSION; GLOMERULUS; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION; KIDNEY INJURY; MALE; MONOTHERAPY; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; PROTEINURIA; RAT; STREPTOZOCIN DIABETES; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; URINARY EXCRETION;

EID: 0038119554     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00127.x     Document Type: Article

References (31)

1. BAYLIS C, HARVEY J, ENGELS K: Acute nitric oxide blockade amplifies the renal vasoconstrictor actions of angiotension II. J Am Soc Nephrol 5:211-214, 1994
2. NAKAMURA T, USHIYAMA C, HIROKAWA K, et al: Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia. Am J Nephrol 21:449-454, 2001
3. TONOLO G, MELIS MG, FORMATO M, et al: Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 30:980-987, 2000
4. KURUSU A, SHOU I, NAKAMURA S, et al: Effects of the new hydroxy-3-methylglutaryl coenzyme a reductase inhibitor fluvastatin on anti-oxidant enzyme activities and renal function in streptozotocin-induced diabetic rats. Clin Exp Pharmacol Physiol 27:767-770, 2000
5. KIM SI, HAN DC, LEE HB: Lovastatin inhibits transforming growth factor-beta1 expression in diabetic rat glomeruli and cultured rat mesangial cells. J Am Soc Nephrol 11:80-87, 2000
6. FRIED LF, ORCHARD TJ, KASISKE BL: Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int 59:260-269, 2001
7. HORIUCHI M, CUI TX, Li Z, et al: Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation. Circulation 107:106-112, 2003
8. ZOJA C, CORNA D, ROTTOLI D, et al: Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney Int 61:1635-1645, 2002
9. ZIYADEH FN, HOFFMAN BB, HAN DC, et al: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal anti-transforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97:8015-8020, 2000
10. GILBERT RE, Cox A, Wu LL, et al: Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: Effects of ACE inhibition. Diabetes 47:414-422, 1998
11. FLYVBJERG A: Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. Diabetologia 43:1205-1223, 2000
12. COOPER ME: Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 44:1957-1972, 2001
13. SOULIS-LIPAROTA T, COOPER ME, DUNLOP M, JERUMS G: The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia 38:387-394, 1995
14. CAO Z, COOPER M, WU L, et al: Blockade of the renin angiotensin and endothelin systems on progressive renal injury. Hypertens 36:561-568, 2000
15. CAO Z, KELLY DJ, COX AJ, et al: The angiotensin type 2 receptor is expressed in adult rat kidney and promotes cellular proliferation and apoptosis. Kidney Int 58:2437-2451, 2000
16. LAN HY, MU W, NIKOLIC-PATERSON DJ, ATKINS RC: A novel, simple, reliable, and sensitive method for multiple immunoenzyme staining: Use of microwave oven heating to block antibody cross-reactivity and retrieve antigens. J Histochem Cytochem 43:97-102, 1995
17. BONNET F, COOPER M, KAWACHI H, et al: Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia 44:874-877, 2001
18. JANDELEIT-DAHM K, CAO Z, Cox AJ, et al: Role of hyperlipidemia in progressive renal disease: Focus on diabetic nephropathy. Kidney Int (Suppl 71):S31-36, 1999
19. NICKENIG G, BAUMER AT, TEMUR Y, et al: Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 100:2131-2134, 1999
20. WASSMANN S, LAUFS U, BAUMER AT, et al: HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertens 37:1450-1457, 2001
21. BORDER WA, NOBLE NA: Transforming growth factor-β in tissue fibrosis. N Engl J Med 331:1286-1392, 1994
22. BORDER WA, NOBLE NA: Evidence that TGF-beta should be a therapeutic target in diabetic nephropathy. Kidney Int 54:1390-1391, 1998
23. PETERS H, BORDER WA, NOBLE NA: Targeting TGF-beta overexpression in renal disease: Maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 54:1570-1580, 1998
24. CAO Z, BONNET F, DAVIS B, et al: Additive hypotensive and antialbuminuric effects of angiotensin converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rat. Clin Sci 100:591-599, 2001
25. BRAUN L, KARDON T, REISZ-PORSZASZ Z, et al: The regulation of the induction of vascular endothelial growth factor at the onset of diabetes in spontaneously diabetic rats Life Sci 69:2533-2542, 2001
26. COOPER ME, VRANES D, YOUSSEF S, et al: Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 48:2229-2239, 1999
27. CHA DR, KIM NH, YOON JW, et al: Role of vascular endothelial growth factor in diabetic nephropathy. Kidney Int 58:S104-S112, 2000
28. AMARAL SL, LINDERMAN JR, MORSE MM, GREENE AS: Angiogenesis induced by electrical stimulation is mediated by angiotensin II and VEGF. Microcirculation 8:57-67, 2001
29. ELISAF M, MIKHAILIDIS DP: Statins and renal function. Angiology 53:493-502, 2002
30. INMAN SR, STOWE NT, CRESSMAN MD, et al: Lovastatin preserves renal function in experimental diabetes. Am J Med Sci 317:215-221, 1999
31. HEART PROTECTION STUDY COLLABORATIVE GROUP: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360:7-22, 2002